CA2604192A1 - Compositions a liberation modifiee contenant un derive de fluorocytidine pour le traitement du cancer - Google Patents

Compositions a liberation modifiee contenant un derive de fluorocytidine pour le traitement du cancer Download PDF

Info

Publication number
CA2604192A1
CA2604192A1 CA002604192A CA2604192A CA2604192A1 CA 2604192 A1 CA2604192 A1 CA 2604192A1 CA 002604192 A CA002604192 A CA 002604192A CA 2604192 A CA2604192 A CA 2604192A CA 2604192 A1 CA2604192 A1 CA 2604192A1
Authority
CA
Canada
Prior art keywords
composition
modified release
dosage form
capecitabine
fluorocytidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002604192A
Other languages
English (en)
Inventor
Scott Jenkins
Gary Liversidge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elan Pharma International Ltd
Original Assignee
Elan Pharma International Limited
Scott Jenkins
Gary Liversidge
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharma International Limited, Scott Jenkins, Gary Liversidge filed Critical Elan Pharma International Limited
Publication of CA2604192A1 publication Critical patent/CA2604192A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002604192A 2005-04-12 2006-04-12 Compositions a liberation modifiee contenant un derive de fluorocytidine pour le traitement du cancer Abandoned CA2604192A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67050705P 2005-04-12 2005-04-12
US60/670,507 2005-04-12
PCT/US2006/013629 WO2006110800A1 (fr) 2005-04-12 2006-04-12 Compositions a liberation modifiee contenant un derive de fluorocytidine pour le traitement du cancer

Publications (1)

Publication Number Publication Date
CA2604192A1 true CA2604192A1 (fr) 2006-10-19

Family

ID=37087358

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002604192A Abandoned CA2604192A1 (fr) 2005-04-12 2006-04-12 Compositions a liberation modifiee contenant un derive de fluorocytidine pour le traitement du cancer

Country Status (7)

Country Link
EP (1) EP1874271A4 (fr)
JP (1) JP2008535920A (fr)
CA (1) CA2604192A1 (fr)
DE (1) DE112006000873T5 (fr)
ES (1) ES2327195B1 (fr)
GB (1) GB2442615A (fr)
WO (1) WO2006110800A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080085310A1 (en) * 2006-10-06 2008-04-10 Maria Oksana Bachynsky Capecitabine rapidly disintegrating tablets
US20110027374A1 (en) * 2008-12-16 2011-02-03 Maria Oksana Bachynsky Capecitabine rapidly disintegrating tablets
RU2017144564A (ru) * 2015-06-13 2019-07-16 Интас Фармасьютикалс Лтд. Капсулы на основе капецитабина с пролонгированным высвобождением
US20190358253A1 (en) * 2017-02-06 2019-11-28 Intas Pharmaceuticals Ltd. Composition comprising immediate release and extended release capecitabine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6586006B2 (en) * 1994-08-04 2003-07-01 Elan Drug Delivery Limited Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
US6110498A (en) * 1996-10-25 2000-08-29 Shire Laboratories, Inc. Osmotic drug delivery system
US6005098A (en) * 1998-02-06 1999-12-21 Hoffmann-La Roche Inc. 5'deoxycytidine derivatives
PT1126826E (pt) * 1998-11-02 2008-11-25 Elan Pharma Int Ltd Composição de metilfenidato de libertação modificada multiparticulada
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
EP1278518B1 (fr) * 2000-02-28 2006-11-08 Pfizer Enterprises SARL Combinaison synergetique pour le traitement du cancer colorectal
KR20030041866A (ko) * 2000-06-02 2003-05-27 매트릭스 파마슈티칼, 인코포레이티드 2′-디옥시-2′-(플루오로메틸렌)시티딘의 제약학적 조성물

Also Published As

Publication number Publication date
EP1874271A1 (fr) 2008-01-09
ES2327195A1 (es) 2009-10-26
ES2327195B1 (es) 2010-07-09
GB0720886D0 (en) 2007-12-05
WO2006110800A1 (fr) 2006-10-19
DE112006000873T5 (de) 2008-03-06
GB2442615A (en) 2008-04-09
EP1874271A4 (fr) 2012-01-25
JP2008535920A (ja) 2008-09-04

Similar Documents

Publication Publication Date Title
US20070122481A1 (en) Modified Release Compositions Comprising a Fluorocytidine Derivative for the Treatment of Cancer
JP6170896B2 (ja) ５−フルオロシトシン製剤およびその使用
KR101633134B1 (ko) 시티딘 유사체의 경구 제형 및 그의 사용 방법
US20070298098A1 (en) Controlled Release Compositions Comprising Levetiracetam
US20060121112A1 (en) Topiramate pharmaceutical composition
AU2016348638A1 (en) Gemcabene combinations for the treatment of cardiovascular disease
KR20170045237A (ko) 항-pd1 또는 항-pdl1 단클론성 항체와 조합된 시티딘 유사체의 경구 제제를 사용한 질환 또는 장애를 치료하는 방법
KR20080059409A (ko) 즉시방출형 및/또는 조절방출형 특성을 가진 약제학적 제형
WO2009035496A1 (fr) Unité de prise nutritionnelle
WO2007092026A1 (fr) Formulations à libération prolongée de dipyridamole et leur procédé de préparation
WO2006088864A1 (fr) Compositions à libération contrôlée comprenant du lévétiracétam
US20070173464A1 (en) Oral ribavirin pharmaceutical compositions
US8992973B2 (en) Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochloride
CA2604192A1 (fr) Compositions a liberation modifiee contenant un derive de fluorocytidine pour le traitement du cancer
CA2609998A1 (fr) Compositions pharmaceutiques orales a base de ribavirine
US20060269596A1 (en) Controlled release compositions comprising an acylanilide
US20200054659A1 (en) Extended release capecitabine capsules
KR20240022574A (ko) 유리한 항-hcv 조합 요법
JP2020514314A (ja) 即時放出及び持続放出カペシタビンを含む組成物
RU123325U1 (ru) Гранула противотуберкулезного лекарственного средства
EP3452054A1 (fr) Composition pharmaceutique de type comprimé-dans-comprimé comprenant du cyclophosphamide et de la capécitabine

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead

Effective date: 20140311